DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-1.07%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$2.67B
AUM Growth
+$2.67B
(-15%)
Cap. Flow
-$330M
Cap. Flow
% of AUM
-12.39%
Top 10 Holdings %
Top 10 Hldgs %
52.23%
Holding
84
New
14
Increased
17
Reduced
20
Closed
22
Top Buys
| 1 |
Cytokinetics
CYTK
|
$88M |
| 2 |
Dynavax Technologies
DVAX
|
$67.2M |
| 3 |
Harmony Biosciences
HRMY
|
$49.9M |
| 4 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$43.8M |
| 5 |
Structure Therapeutics
GPCR
|
$42.8M |
Top Sells
| 1 |
argenx
ARGX
|
$198M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$108M |
| 3 |
Intellia Therapeutics
NTLA
|
$102M |
| 4 |
Alkermes
ALKS
|
$98M |
| 5 |
Axsome Therapeutics
AXSM
|
$77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Dynavax Technologies
DVAX
$1.19B
| $227M | 8.47% | 17,791,486 +5,265,000 | +42% | +$67.2M |
|
2
Guardant Health
GH
$8.41B
| $196M | 7.32% | 6,419,566 +419,006 | +7% | +$12.8M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $167M | 6.23% | 2,000,000 +399,307 | +25% | +$33.4M |
|
4
Immunovant
IMVT
$2.56B
| $149M | 5.54% | 6,000,000 +1,652,536 | +38% | +$40.9M |
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $136M | 5.09% | 4,274,921 -125,733 | -3% | -$4.01M |
|
|
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
| $125M | 4.66% | 3,460,756 -383,144 | -10% | -$13.8M |
|
|
7
Cytokinetics
CYTK
$4.23B
| $118M | 4.39% | 2,500,000 +1,870,094 | +297% | +$88M |
|
8
Ocular Therapeutix
OCUL
$2.12B
| $110M | 4.09% | 12,836,282 +114,822 | +0.9% | +$981K |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $86.7M | 3.23% | 4,522,741 +771,796 | +21% | +$14.8M |
|
10
Pliant Therapeutics
PLRX
$101M
| $78.7M | 2.93% | 5,972,257 | – | – |
|
|
11
Structure Therapeutics
GPCR
$1.11B
| $75.9M | 2.83% | 2,800,000 +1,579,492 | +129% | +$42.8M |
|
12
Ionis Pharmaceuticals
IONS
$6.79B
| $67.6M | 2.52% | 1,933,928 -266,072 | -12% | -$9.3M |
|
13
Nurix Therapeutics
NRIX
$714M
| $56.5M | 2.11% | 3,000,000 -868,104 | -22% | -$16.4M |
|
|
MBX
14
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $55.6M | 2.08% | 3,018,935 | – | – |
|
15
89bio
ETNB
$1.34B
| $50.7M | 1.89% | 6,478,249 +3,711,737 | +134% | +$29M |
|
|
16
Harmony Biosciences
HRMY
$2.12B
| $49.9M | 1.86% | +1,450,000 | New | +$49.9M |
|
17
Dyne Therapeutics
DYN
$1.92B
| $47.1M | 1.76% | 2,000,000 -1,282,000 | -39% | -$30.2M |
|
|
SEPN
18
Septerna, Inc. Common Stock
SEPN
$539M
| $43.8M | 1.63% | +1,912,929 | New | +$43.8M |
|
19
Neumora Therapeutics
NMRA
$280M
| $42.4M | 1.58% | 4,000,000 +3,432,572 | +605% | +$36.4M |
|
20
Genmab
GMAB
$15.3B
| $41.7M | 1.56% | +2,000,000 | New | +$41.7M |
|
21
Akero Therapeutics
AKRO
$3.74B
| $41.5M | 1.55% | 1,490,000 +800,216 | +116% | +$22.3M |
|
|
VRNA
22
Verona Pharma
VRNA
$9.16B
| $39.5M | 1.47% | 850,000 -2,330,025 | -73% | -$108M |
|
23
Celldex Therapeutics
CLDX
$1.47B
| $38.9M | 1.45% | +1,540,132 | New | +$38.9M |
|
24
Protagonist Therapeutics
PTGX
$3.67B
| $38.6M | 1.44% | +1,000,000 | New | +$38.6M |
|
25
ANI Pharmaceuticals
ANIP
$2.03B
| $35.9M | 1.34% | 649,042 +144,214 | +29% | +$7.97M |
|